NR4A1 and breast cancer: HER2E tumors indicated as HRD-positive may also benefit from a combination of neo-adjuvant chemotherapy and a PARP inhibitor, considering results from the GeparOLA study within early HER2-negative HRD-positive breast cancer, where patients with hormone receptor-positive tumors exhibited higher response rates52,53.